Blood: Adding rapamycin to the GVHD prevention program can significantly improve the prognosis of HCT patients with HLA antigen mismatch
-
Last Update: 2020-07-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
the purpose !---- of this study is to evaluate the efficacy of adding rapamycin to postoperative hematopoietic cell transplantation (HCT) anti-host disease (GVHD) in the treatment of cyclosporine and McOxaloxaterecruit patients with blood malignant diseases who can be treated with allogeneic HCTconditioning options include fludarabin (90 mg/m2) and 2-3 Gy full body radiotherapyGVHD prevention is cyclosporine and mcoxelateest and rapamycinthe main indicator of assessment is whether the cumulative incidence of type II-IV acute GVHD can be reduced to less than 70% in HCT patients with type I or TYPE II HLA mismatchesas of December 12, 2018, 77 subjects were recruited, 76 of whom completed the study interventionmedian follow-up for 47 months (range 4-94)100 days, the cumulative incidence of ii-IV acute GVHD was 36% (95% CI 25-46), reaching the primary endpointAfter 4 years, the incidence of non-recurrence dysoration and cumulative recurrence/progression was 18% (95% CI 9-27) and 30% (IQR 19-40), respectively, with an overall survival rate of 62% (95% CI 50-73%) respectivelyin general, adding rapamycin to the combined programme of cyclosporine and McPhee can reduce the incidence of acute GVHD, thereby increasing the overall survival rate of patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
